Sanofi Secures EU Approval For MenQuadfi In Infants From Six Weeks, Backed By Immunogenicity Data From Pivotal MET58 Study
Share
Why It Matters
Sanofi got permission to sell a meningitis vaccine for tiny babies starting at six weeks old, based on test results showing it works. This is good news for the company's vaccine business, so watch if investors get more interested in Sanofi's health products.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.